Caris Life Sciences, Inc. filings document financial results, governance matters, financing arrangements and material company events for an AI TechBio precision medicine business. Form 8-K disclosures report quarterly and annual operating results, molecular profiling services revenue, clinical therapy selection activity, and Regulation FD updates tied to company presentations and diagnostic-development programs.
The company’s SEC record also includes a definitive proxy statement covering annual meeting proposals, director elections and auditor ratification. Other material-event filings describe senior secured credit facilities with subsidiary guarantees, amendments to bylaws affecting shareholder derivative proceedings, and capital-structure terms relevant to Caris’ public-company reporting obligations.
Caris Life Sciences reported strong Q1 2026 growth with total revenue of $216.174 million, up from $120.915 million a year earlier, driven mainly by molecular profiling services. The company generated income from operations of $5.282 million versus a prior operating loss and kept net loss nearly flat at $0.510 million.
Adjusted EBITDA improved to $26.2 million, and free cash flow turned positive at $22.5 million. Caris ended the quarter with $825.705 million in cash, cash equivalents, restricted cash and marketable securities and had $400.0 million of term loan debt outstanding before refinancing after quarter-end.
Caris Life Sciences reported a strong first quarter of 2026 as revenue and profitability metrics improved sharply. Total revenue reached $216.2 million, up 79% from the prior-year quarter, driven by $210.8 million in molecular profiling services revenue, which grew 85%. The company completed about 52,800 clinical therapy selection cases, a 15% increase, and delivered a gross margin of 65%, up from 47%.
Operating income was positive and net loss narrowed to just $0.5 million, with Adjusted EBITDA of $26.2 million. Cash generation improved markedly: operating cash flow was $32.9 million and free cash flow was $22.5 million, even after $30.5 million in annual bonus payments. Management reaffirmed 2026 revenue guidance of $1.0–$1.02 billion, implying 23%–26% growth over 2025, and about 20% clinical therapy selection volume growth.
Caris Life Sciences, Inc. is asking shareholders to vote at its June 4, 2026 virtual annual meeting on two items: electing ten directors to one‑year terms and ratifying Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026.
The board is led by founder, Chairman and CEO David Dean Halbert, with Peter M. Castleman serving as lead independent director. A majority of directors are classified as independent under Nasdaq rules, and the board maintains separate Audit and Compensation Committees composed entirely of independent members.
The proxy details 2025 executive pay, including total compensation of $20,350,571 for Mr. Halbert and $11,583,227 for President David Spetzler, driven largely by RSU and option awards granted around the June 2025 IPO. Senior executives have severance protections and participate in a change‑in‑control equity vesting plan, and the company operates multiple shareholder‑approved equity plans.
FMR LLC filed Amendment No. 1 to a Schedule 13G reporting beneficial ownership of 30,631,585 shares of Common Stock of Caris Life Sciences Inc. representing 10.8% of the class. The amendment lists sole voting power of 30,592,295 shares and sole dispositive power of 30,631,585, and cites related power-of-attorney exhibits.
Caris Life Sciences, Inc. entered into a new senior secured credit agreement on April 1, 2026, providing an initial term loan of $400,000,000, a committed delayed draw term facility of up to $300,000,000, and an uncommitted incremental facility of up to $500,000,000.
The initial term loan funded at closing and matures in April 2031, while the delayed draw facility is available through August 2027 and may be used only for Permitted Acquisitions. Loans bear interest at a Term SOFR or Base Rate option plus margins of 5.00% or 4.00%, respectively, for the term and delayed draw loans.
The facilities are guaranteed by certain subsidiaries and secured by substantially all tangible and intangible personal property. The agreement includes customary covenants and events of default, and requires minimum qualified cash of $50 million at each fiscal quarter-end. The company used proceeds from the initial term loan to fully repay and terminate its January 18, 2023 credit agreement, including related guarantees and liens.
Power Luke Thomas reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. executive Luke Thomas Power received an equity grant in the form of restricted stock units. The award covers 63,971 shares of Common Stock, granted at no cash cost to him as compensation. According to the footnote, these restricted stock units will vest in line with the terms of the applicable grant agreement. Following this grant, he directly holds 163,542 shares of Common Stock.
Denton John Russel reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. officer John Russel Denton received a grant of 63,971 shares of Common Stock on March 6, 2026, reported as restricted stock units that will vest under the applicable grant agreement. Following this grant, he holds 187,562 shares directly and 9,184 shares indirectly through a trust.
Spetzler David Baxley reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. President David Baxley Spetzler received an award of 83,162 shares of Common Stock in the form of restricted stock units. The award was granted at no cash cost per share and will vest in accordance with the applicable grant agreement. Following this compensation-related grant, he holds 543,939 shares of Common Stock directly.
Brille Brian J reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director and officer Brian J. Brille received a grant of 83,162 shares of Common Stock in the form of restricted stock units on March 6, 2026, at no cash cost, as compensation that will vest under the applicable grant agreement.
Following this grant, he directly holds 244,290 Common shares. In addition, a family trust holds 500,000 Common shares, with Brille reporting the position indirectly and disclaiming beneficial ownership except for his pecuniary interest.